Anthony R. Mato
Expertise in
22
conditions

Dr. Anthony R. Mato

Oncology | Hematology
Arnot Ogden Medical Center
600 Roe Ave, 
Elmira, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
22
conditions
Arnot Ogden Medical Center
600 Roe Ave, 
Elmira, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anthony Mato is an Oncologist and a Hematologist in Elmira, New York. Dr. Mato is highly rated in 22 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Arnot Ogden Medical Center
Schuyler Hospital
Cayuga Medical Center At Ithaca
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ARNOT OGDEN MEDICAL CENTER
600 Roe Ave, Elmira, NY 14905
Other Locations
CAYUGA MEDICAL CENTER AT ITHACA
101 Dates Dr, Ithaca, NY 14850

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Enrollment Status: Recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Venetoclax+anti CD20 monoclonal antibody
Study Phase: Phase 2
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Study Phase: Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other
View 8 Less Clinical Trials

175 Total Publications

Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 04, 2024
Similar Doctors
Expertise in
7
conditions
Dr. Giampaolo Talamo
Oncology | Hematology
Expertise in
7
conditions
Dr. Giampaolo Talamo
Oncology | Hematology

Guthrie Medical Group PC

1 Guthrie Sq, 
Sayre, PA 
 (17.0 miles away)
570-888-5858
Languages Spoken:
English
See accepted insurances

Giampaolo Talamo is an Oncologist and a Hematologist in Sayre, Pennsylvania. Dr. Talamo is highly rated in 7 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
34
conditions
Dr. Alina Basnet
Hematology | Oncology
Expertise in
34
conditions
Dr. Alina Basnet
Hematology | Oncology

Guthrie Medical Group PC

34 W Main St, 
Cortland, NY 
 (45.8 miles away)
607-756-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alina Basnet is a Hematologist and an Oncologist in Cortland, New York. Dr. Basnet is highly rated in 34 conditions, according to our data. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Urothelial Cancer, Bone Marrow Aspiration, and Nephrectomy. Dr. Basnet is currently accepting new patients.

Bernard Poiesz
Expertise in
21
conditions
Dr. Bernard Poiesz
Hematology | Oncology
Expertise in
21
conditions
Dr. Bernard Poiesz
Hematology | Oncology

Auburn Community Hospital

17 Lansing St, 
Auburn, NY 
 (59.6 miles away)
315-255-7142
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bernard Poiesz is a Hematologist and an Oncologist in Auburn, New York. Dr. Poiesz is highly rated in 21 conditions, according to our data. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Small Lymphocytic Lymphoma (SLL), Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mato's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 72 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile